CORDIS
EU research results

CORDIS

English EN

In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy

Project information

Grant agreement ID: 777204

Status

Ongoing project

  • Start date

    1 June 2018

  • End date

    30 November 2021

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 5 507 441,25

  • EU contribution

    € 5 507 441,25

Coordinated by:

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

Serbia

Objective

According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural and functional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery disease or abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated (DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC).
Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, through in vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). The treatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapies need to be developed to affect the disease process and time course more fundamentally.
SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flow molecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing tools with state of the art computer models with the aim to reduce animal and clinical studies for a new drug development and optimized clinical therapy of FCM.
The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and high-performance computing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV, UPMC and UHREG will do retrospective and prospective studies. SME partner R-Tech will be in charge of regulatory issues and reports and BIOIRC will do the exploitation of the project.

Coordinator

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

Address

Prvoslava Stojanovica Street 6
34000 Kragujevac

Serbia

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 653 000

Participants (13)

Illinois Institute of Technology

United States

EU Contribution

€ 417 750

UNIVERSITY OF KENT

United Kingdom

EU Contribution

€ 413 550

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 604 090

UNIVERSITA DEGLI STUDI DI FIRENZE

Italy

EU Contribution

€ 327 475

INSTITUT ZA KARDIOVASKULARNE BOLESTI VOJVODINE

Serbia

EU Contribution

€ 445 750

SORBONNE UNIVERSITE

France

EU Contribution

€ 396 625

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 374 625

PANEPISTIMIO IOANNINON

Greece

EU Contribution

€ 276 375

BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION

Spain

EU Contribution

€ 342 375

UNIVERZA V LJUBLJANI

Slovenia

EU Contribution

€ 187 500

STEINBEIS ADVANCED RISK TECHNOLOGIES GMBH

Germany

EU Contribution

€ 278 750

UNIVERSITY OF WASHINGTON

United States

EU Contribution

€ 450 201,25

SEVEN BRIDGES GENOMICS INC

United States

EU Contribution

€ 339 375

Project information

Grant agreement ID: 777204

Status

Ongoing project

  • Start date

    1 June 2018

  • End date

    30 November 2021

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 5 507 441,25

  • EU contribution

    € 5 507 441,25

Coordinated by:

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

Serbia